Plain-English translation of NCT06637631 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn's Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called to see if it can help people with moderate to severe Crohn's disease. The trial will compare different doses of this medication against a placebo (an inactive treatment) to find out which dose works best and how safe it is. About 260 people will participate across multiple hospitals and clinics worldwide.
Many people with Crohn's disease don't respond well enough to current treatments or stop responding over time. This trial is testing whether the medication might offer a new option for patients whose disease isn't controlled by standard therapies.
You likely qualify if…
You likely don't qualify if…
The study lasts about 59 weeks total. You'll start with a 4-week screening period, then enter the main treatment phase lasting 52 weeks—12 weeks of initial treatment followed by 40 weeks of maintenance. You'll be randomly assigned to receive either one of three doses of the medication or a placebo. Throughout the study, you'll have regular clinic visits for checkups, blood tests, and possibly an endoscopy. Some participants may be offered an additional open-label period where everyone knows they're receiving the active medication.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States